8-K: Mural Oncology Shareholders Re-Elect Directors and Ratify Auditor at 2025 Annual Meeting

Mural Oncology plc announced the successful re-election of all six director nominees and the ratification of PricewaterhouseCoopers LLP as its independent auditor at its 2025 Annual General Meeting.

Summary

• Mural Oncology plc held its 2025 Annual General Meeting (AGM) on June 11, 2025.
• Shareholders re-elected six directors to serve until the 2026 annual general meeting: Francis Cuss, M.B., B.Chir., FRCP; George Golumbeski, Ph.D.; Benjamin Hickey, MBA; Scott Jackson, MBA; Caroline Loew, Ph.D.; and Sachiyo Minegishi, MBA.
• All director nominees received overwhelming support, with 'For' votes significantly outnumbering 'Against' votes (e.g., Francis Cuss received 5,883,909 'For' votes against 596,030 'Against' votes).
• Shareholders ratified the selection of PricewaterhouseCoopers LLP as the company's independent auditor for the fiscal year ending December 31, 2025, in a non-binding vote.
• The board of directors, acting through the audit committee, was authorized in a binding vote to set the independent auditor's remuneration.
• The auditor ratification proposal passed with 11,918,446 'For' votes against 190,443 'Against' votes.

Sentiment

Score: 8

Explanation: The sentiment is positive as all proposals passed with significant shareholder approval, indicating stable corporate governance and shareholder confidence in the current leadership and oversight.

Positives

• All six director nominees were successfully re-elected with strong shareholder support, indicating confidence in the current board.
• The ratification of PricewaterhouseCoopers LLP as the independent auditor passed with an overwhelming majority, ensuring continuity and compliance with financial oversight.

Future Outlook

This document does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook, focusing solely on the results of the Annual General Meeting.

Industry Context

This announcement pertains to routine corporate governance matters for a publicly traded oncology company, reflecting standard practices for shareholder engagement and oversight within the pharmaceutical and biotechnology sectors. The successful re-election of directors and ratification of auditors are typical outcomes for well-governed companies.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Their votes directly determined the composition of the board and the appointment of the independent auditor, affirming their governance rights.
• Board of Directors: The re-election of all nominees indicates continued mandate and support from the shareholders.
• Management: The stability of the board provides a consistent governance framework for management operations.

Next Steps

• The re-elected directors will serve until the company's 2026 annual general meeting.
• PricewaterhouseCoopers LLP will serve as the independent auditor for the fiscal year ending December 31, 2025.

Key Dates

Keywords

Mural Oncology, AGM, Annual General Meeting, Director Election, Auditor Ratification, Corporate Governance, SEC Filing, 8-K, Shareholder Vote, PricewaterhouseCoopers